Adrenaline

Overview

Adrenaline, also known as epinephrine and alternatively spelled adrenalin, is a hormone and medication which is involved in regulating visceral functions (e.g., respiration). It appears as a white microcrystalline granule. Adrenaline is normally produced by the adrenal glands and by a small number of neurons in the medulla oblongata. It plays an essential role in the fight-or-flight response by increasing blood flow to muscles, heart output by acting on the SA node, pupil dilation response, and blood sugar level. It does this by binding to alpha and beta receptors. It is found in many animals, including humans, and some single-celled organisms. It has also been isolated from the plant Scoparia dulcis found in Northern Vietnam.[1–11] WP

Uses, dosage and effects

Medical uses

As a medication, it is used to treat several conditions, including allergic reaction anaphylaxis, cardiac arrest, and superficial bleeding. Inhaled adrenaline may be used to improve the symptoms of croup. It may also be used for asthma when other treatments are not effective. It is given intravenously, by injection into a muscle, by inhalation, or by injection just under the skin. Common side effects include shakiness, anxiety, and sweating. A fast heart rate and high blood pressure may occur. Occasionally it may result in an abnormal heart rhythm. While the safety of its use during pregnancy and breastfeeding is unclear, the benefits to the mother must be taken into account.[12][13] WP

A case has been made for the use of adrenaline infusion in place of the widely accepted treatment of inotropes for preterm infants with clinical cardiovascular compromise. Although sufficient data strongly recommends adrenaline infusions as a viable treatment, more trials are needed to conclusively determine that these infusions will successfully reduce morbidity and mortality rates among preterm, cardiovascularly compromised infants.[14] WP

Epinephrine can also be used to treat open-angle glaucoma, as it increases the outflow of aqueous humor from the eye, which lowers intraocular pressure.[15] WP

Physiological effects

The adrenal medulla is a major contributor to total circulating catecholamines (L-DOPA is at a higher concentration in the plasma), though it contributes over 90% of circulating adrenaline. Little adrenaline is found in other tissues, mostly in scattered chromaffin cells and in a small number of neurons that use adrenaline as a neurotransmitter. Following adrenalectomy, adrenaline disappears below the detection limit in the bloodstream.[16][17][18] WP

Pharmacological doses of adrenaline stimulate α₁, α₂, β₁, β₂, and β₃ adrenoceptors of the sympathetic nervous system. Sympathetic nerve receptors are classified as adrenergic, based on their responsiveness to adrenaline. The term "adrenergic" is often misinterpreted in that the main sympathetic neurotransmitter is noradrenaline, rather than adrenaline, as discovered by Ulf von Euler in 1946. Adrenaline has a β₂ adrenoceptor-mediated effect on metabolism and the airway, with no direct neural connection from the sympathetic ganglia to the airway.[19–24] WP

Walter Bradford Cannon originally proposed the concept of the adrenal medulla and the sympathetic nervous system being involved in the flight, fight, and fright response. But the adrenal medulla, in contrast to the adrenal cortex, is not required for survival. In adrenalectomized patients, hemodynamic and metabolic responses to stimuli such as hypoglycemia and exercise remain normal.[25][26] WP

Exercise

One physiological stimulus to adrenaline secretion is exercise. This was first demonstrated by measuring the dilation of a (denervated) pupil of a cat on a treadmill, later confirmed using a biological assay of urine samples. Biochemical methods for measuring catecholamines in plasma were published from 1950 onwards. Although much valuable work has been published using fluorimetric assays to measure total catecholamine concentrations, the method is too non-specific and insensitive to accurately determine the very small quantities of adrenaline in plasma. The development of extraction methods and enzyme–isotope derivate radio-enzymatic assays (REA) transformed the analysis down to a sensitivity of 1 pg for adrenaline. Early REA plasma assays indicated that adrenaline and total catecholamines rise late in exercise, mostly when anaerobic metabolism commences.[27–33] WP

During exercise, the adrenaline blood concentration rises partially from the increased secretion of the adrenal medulla and partly from the decreased metabolism of adrenaline due to reduced blood flow to the liver. Infusion of adrenaline to reproduce exercise circulating concentrations of adrenaline in subjects at rest has little hemodynamic effect other than a slight β₂-mediated fall in diastolic blood pressure. Infusion of adrenaline well within the physiological range suppresses human airway hyper-reactivity sufficiently to antagonize the constrictor effects of inhaled histamine.[34–37] WP

A link between the sympathetic nervous system and the lungs was shown in 1887 when Grossman showed that stimulation of cardiac accelerator nerves reversed muscarine-induced airway constriction. In experiments in the dog, where the sympathetic chain was cut at the level of the diaphragm, Jackson showed that there was no direct sympathetic innervation to the lung, but bronchoconstriction was reversed by the release of adrenaline from the adrenal medulla. An increased incidence of asthma has not been reported for adrenalectomized patients; those with a predisposition to asthma will have some protection from airway hyper-reactivity from their corticosteroid replacement therapy. Exercise induces progressive airway dilation in normal subjects that correlates with workload and is not prevented by beta-blockade. The progressive airway dilation with increasing exercise is mediated by a progressive reduction in resting vagal tone. Beta blockade with propranolol causes a rebound in airway resistance after exercise in normal subjects over the same time course as the bronchoconstriction seen with exercise-induced asthma. The reduction in airway resistance during exercise reduces the work of breathing.[38–42] WP

Emotional responses

Every emotional response has a behavioral, an autonomic, and a hormonal component. The hormonal component includes the release of adrenaline, an adrenomedullary response to stress controlled by the sympathetic nervous system. The major emotion studied in relation to adrenaline is fear. In an experiment, subjects who were injected with adrenaline expressed more negative and fewer positive facial expressions to fear films compared to a control group. These subjects also reported a more intense fear from the films and greater mean intensity of negative memories than control subjects. The findings from this study demonstrate that there are learned associations between negative feelings and levels of adrenaline. Overall, the greater amount of adrenaline is positively correlated with an aroused state of negative emotions. These findings can be an effect in part that adrenaline elicits physiological sympathetic responses, including an increased heart rate and knee shaking, which can be attributed to the feeling of fear regardless of the actual level of fear elicited from the video. Although studies have found a definite relation between adrenaline and fear, other emotions have not had such results. In the same study, subjects did not express a greater amusement to an amusement film nor greater anger to an anger film. Similar findings were also supported in a study that involved rodent subjects that either were able or unable to produce adrenaline. Findings support the idea that adrenaline has a role in facilitating the encoding of emotionally arousing events, contributing to higher levels of arousal due to fear.[43][44] WP

Memory

It has been found that adrenergic hormones, such as adrenaline, can produce retrograde enhancement of long-term memory in humans. The release of adrenaline due to emotionally stressful events, which is endogenous adrenaline, can modulate memory consolidation of the events, ensuring memory strength that is proportional to memory importance. Post-learning adrenaline activity also interacts with the degree of arousal associated with the initial coding. There is evidence that suggests adrenaline does have a role in long-term stress adaptation and emotional memory encoding specifically. Adrenaline may also play a role in elevating arousal and fear memory under particular pathological conditions, including post-traumatic stress disorder. Overall, "Extensive evidence indicates that epinephrine (EPI) modulates memory consolidation for emotionally arousing tasks in animals and human subjects." Studies have also found that recognition memory involving adrenaline depends on a mechanism that depends on β adrenoceptors. Adrenaline does not readily cross the blood-brain barrier, so its effects on memory consolidation are at least partly initiated by β adrenoceptors in the periphery. Studies have found that sotalol, a β adrenoceptor antagonist that also does not readily enter the brain, blocks the enhancing effects of peripherally administered adrenaline on memory. These findings suggest that β adrenoceptors are necessary for adrenaline to have an impact on memory consolidation.[44–49] WP

Pharmacology

Mechanism of action

As a hormone, adrenaline acts on nearly all body tissues by binding to adrenergic receptors. Its effects on various tissues depend on the type of tissue and expression of specific forms of adrenergic receptors. For example, high levels of adrenaline cause smooth muscle relaxation in the airways but causes contraction of the smooth muscle that lines most arterioles. WP

Adrenaline is a nonselective agonist of all adrenergic receptors, including the major subtypes α₁, α₂, β₁, β₂, and β₃. Adrenaline's binding to these receptors triggers a number of metabolic changes. Binding to α-adrenergic receptors inhibits insulin secretion by the pancreas, stimulates glycogenolysis in the liver and muscle, and stimulates glycolysis and inhibits insulin-mediated glycogenesis in muscle. β adrenergic receptor binding triggers glucagon secretion in the pancreas, increased adrenocorticotropic hormone (ACTH) secretion by the pituitary gland, and increased lipolysis by adipose tissue. Together, these effects increase blood glucose and fatty acids, providing substrates for energy production within cells throughout the body. Binding of β adrenergic receptor also increases the production of cyclic AMP.[50–54] WP

Adrenaline causes liver cells to release glucose into the blood, acting through both alpha and beta-adrenergic receptors to stimulate glycogenolysis. Adrenaline binds to β₂ receptors on liver cells, which changes conformation and helps Gₛ, a heterotrimeric G protein, exchange GDP to GTP. This trimeric G protein dissociates to Gₛ alpha and Gₛ beta/gamma subunits. Gₛ alpha stimulates adenylyl cyclase, thus converting adenosine triphosphate into cyclic adenosine monophosphate (AMP). Cyclic AMP activates protein kinase A. Protein kinase A phosphorylates and partially activates phosphorylase kinase. Adrenaline also binds to α₁ adrenergic receptors, causing an increase in inositol trisphosphate, inducing calcium ions to enter the cytoplasm. Calcium ions bind to calmodulin, which leads to further activation of phosphorylase kinase. Phosphorylase kinase phosphorylates glycogen phosphorylase, which then breaks down glycogen leading to the production of glucose.[55] WP

Adrenaline also has significant effects on the cardiovascular system. It increases peripheral resistance via α₁ receptor-dependent vasoconstriction and increases cardiac output by binding to β₁ receptors. The goal of reducing peripheral circulation is to increase coronary and cerebral perfusion pressures and therefore increase oxygen exchange at the cellular level. While adrenaline does increase aortic, cerebral, and carotid circulation pressure, it lowers carotid blood flow and end-tidal CO₂ or ETCO₂ levels. It appears that adrenaline improves microcirculation at the expense of the capillary beds where perfusion takes place.[56][57][58] WP

History

History

Extracts of the adrenal gland were first obtained by Polish physiologist Napoleon Cybulski in 1895. These extracts, which he called nadnerczyna ("adrenalin"), contained adrenaline and other catecholamines. American ophthalmologist William H. Bates discovered adrenaline's usage for eye surgeries prior to 20 April 1896. In 1897, John Jacob Abel (1857–1938), the father of modern pharmacology, found a natural substance produced by the adrenal glands that he named epinephrine. The first hormone to be identified, it remains a crucial, first-line treatment for cardiac arrests, severe allergic reactions, and other conditions. In 1901, Jokichi Takamine successfully isolated and purified the hormone from the adrenal glands of sheep and oxen. Adrenaline was first synthesized in the laboratory by Friedrich Stolz and Henry Drysdale Dakin, independently, in 1904.[59–63] WP

Although secretin is mentioned as the first hormone, adrenaline is the first hormone since the discovery of the activity of adrenal extract on blood pressure was observed in 1895 before that of secretin in 1902. In 1895, George Oliver (1841–1915), a general practitioner in North Yorkshire, and Edward Albert Schäfer (1850–1935), a physiologist at University College of London published a paper about the active component of adrenal gland extract causing the increase in blood pressure and heart rate was from the medulla, but not the cortex of the adrenal gland. In 1897, John Jacob Abel (1857–1938) of Johns Hopkins University, the first chairman of the first US department of pharmacology, found a compound called epinephrine with the molecular formula of C₁₇H₁₅NO₄. Abel claimed his principle from adrenal gland extract was active.[64][65] WP

In 1900, Jōkichi Takamine (1854–1922), a Japanese chemist, worked with his assistant, Keizo Uenaka (1876–1960), to purify a 2000 times more active principle than epinephrine from the adrenal gland, named adrenaline with the molecular formula C₁₀H₁₅NO₃. Additionally, in 1900 Thomas Aldrich of Parke-Davis Scientific Laboratory also purified adrenaline independently. Takamine and Parke-Davis later in 1901 both got the patent for adrenaline. The fight for terminology between adrenaline and epinephrine was not ended until the first adrenaline structural discovery by Hermann Pauly (1870–1950) in 1903 and the first adrenaline synthesis by Friedrich Stolz (1860–1936), a German chemist in 1904. Stolz synthesized adrenaline from its ketone form (adrenalone).[64][65][66] WP

Legal status

Regulation

The major physiologic triggers of adrenaline release center upon stresses, such as physical threat, excitement, noise, bright lights, and high or low ambient temperature. All of these stimuli are processed in the central nervous system.[67] WP

Adrenocorticotropic hormone (ACTH) and the sympathetic nervous system stimulate the synthesis of adrenaline precursors by enhancing the activity of tyrosine hydroxylase and dopamine β-hydroxylase, two key enzymes involved in catecholamine synthesis. ACTH also stimulates the adrenal cortex to release cortisol, which increases the expression of PNMT in chromaffin cells, enhancing adrenaline synthesis. This is most often done in response to stress. The sympathetic nervous system, acting via splanchnic nerves to the adrenal medulla, stimulates the release of adrenaline. Acetylcholine released by preganglionic sympathetic fibers of these nerves acts on nicotinic acetylcholine receptors, causing cell depolarization and an influx of calcium through voltage-gated calcium channels. Calcium triggers the exocytosis of chromaffin granules and, thus, the release of adrenaline (and noradrenaline) into the bloodstream. For noradrenaline to be acted upon by PNMT in the cytosol, it must first be shipped out of granules of the chromaffin cells. This may occur via the catecholamine-H⁺ exchanger VMAT1. VMAT1 is also responsible for transporting newly synthesized adrenaline from the cytosol back into chromaffin granules in preparation for release.[68] WP⚠ Wikipedia itself has flagged this text: citation needed.

Unlike many other hormones, adrenaline (as with other catecholamines) does not exert negative feedback to down-regulate its own synthesis. Abnormal adrenaline levels can occur in various conditions, such as surreptitious adrenaline administration, pheochromocytoma, and other tumors of the sympathetic ganglia. WP

Its action is terminated with reuptake into nerve terminal endings, some minute dilution, and metabolism by monoamine oxidase and catechol-O-methyl transferase into 3,4-Dihydroxymandelic acid and Metanephrine.[69] WP

Adrenaline junkie

An adrenaline junkie is someone who "has a compulsive desire for extreme excitement". Such activities include extreme and risky sports, substance abuse, unsafe sex, and crime. The term relates to the increase in circulating levels of adrenaline during physiological stress. Such an increase in the circulating concentration of adrenaline is secondary to the activation of the sympathetic nerves innervating the adrenal medulla, as it is rapid and not present in animals where the adrenal gland has been removed. Although such stress triggers adrenaline release, it also activates many other responses within the central nervous system reward system, which drives behavioral responses; while the circulating adrenaline concentration is present, it may not drive behavior. Nevertheless, adrenaline infusion alone does increase alertness and has roles in the brain, including the augmentation of memory consolidation.[70][71][72] WP

Strength

Adrenaline has been implicated in feats of great strength, often occurring in times of crisis. For example, there are stories of a parent lifting part of a car when their child is trapped underneath, showcasing the ability of the body to endure under stress and highlighting the significant effects of adrenaline in unlocking extraordinary physical abilities.[73][74] WP

Chemistry

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Lieberman M, Marks A, Peet A. Marks' Basic Medical Biochemistry: A Clinical Approach. 2013
2. Other Adrenaline. 21 August 2015
3. Other Malenka RC, Nestler EJ, Hyman SE. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. 2009
4. Other Larrañaga M. Hawley's Condensed Chemical Dictionary. 2016
5. Other Adrenaline: physiology and pharmacology | DermNet
6. Journal / agency Brown HF, DiFrancesco D, Noble SJ. How does adrenaline accelerate the heart?. Nature. July 1979. doi:10.1038/280235a0 · PMID 450140
7. Other Bell DR. Medical physiology: principles for clinical medicine. 2009
8. Other Khurana I. Essentials of Medical Physiology. 2008
9. Other Buckley E. Venomous Animals and Their Venoms: Venomous Vertebrates. 2013
10. Other Animal Physiology: Adaptation and Environment. 1997
11. Journal / agency Phan MG, Phan TS, Matsunami K, Otsuka H. Chemical and biological evaluation on scopadulane-type diterpenoids from Scoparia dulcis of Vietnamese origin. Chemical & Pharmaceutical Bulletin. April 2006. doi:10.1248/cpb.54.546 · PMID 16595962
12. Other Epinephrine
13. Journal / agency Everard ML. Acute bronchiolitis and croup. Pediatric Clinics of North America. February 2009. doi:10.1016/j.pcl.2008.10.007 · PMID 19135584
14. Journal / agency Paradisis M, Osborn DA. Adrenaline for prevention of morbidity and mortality in preterm infants with cardiovascular compromise. The Cochrane Database of Systematic Reviews. 2004. doi:10.1002/14651858.CD003958.pub2 · PMID 14974048 · PMC12159978
15. Journal / agency Erickson-Lamy KA, Nathanson JA. Epinephrine increases facility of outflow and cyclic AMP content in the human eye in vitro. Investigative Ophthalmology & Visual Science. August 1992. PMID 1353486
16. Journal / agency Rizzo V, Memmi M, Moratti R, Melzi d'Eril G, Perucca E. Concentrations of L-dopa in plasma and plasma ultrafiltrates. Journal of Pharmaceutical and Biomedical Analysis. June 1996. doi:10.1016/s0731-7085(96)01753-0 · PMID 8818013
17. Journal / agency Fuller RW. Pharmacology of brain epinephrine neurons. Annual Review of Pharmacology and Toxicology. April 1982. doi:10.1146/annurev.pa.22.040182.000335 · PMID 6805416
18. Journal / agency Cryer PE. Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system. The New England Journal of Medicine. August 1980. doi:10.1056/nejm198008213030806 · PMID 6248784
19. Journal / agency Barger G, Dale HH. Chemical structure and sympathomimetic action of amines. The Journal of Physiology. October 1910. doi:10.1113/jphysiol.1910.sp001392 · PMID 16993040 · PMC1513032
20. Journal / agency Von Euler US. A specific sympathomimetic ergone in adrenergic nerve fibres (sympathin) and its relations to adrenaline and nor adrenaline. Acta Physiologica Scandinavica. 1946. doi:10.1111/j.1748-1716.1946.tb00368.x
21. Journal / agency Von Euler US, Hillarp NA. Evidence for the presence of noradrenaline in submicroscopic structures of adrenergic axons. Nature. January 1956. doi:10.1038/177044b0 · PMID 13288591
22. Journal / agency Warren J. The adrenal medulla and the airway. British Journal of Diseases of the Chest. January 1986. doi:10.1016/0007-0971(86)90002-1 · PMID 3004549
23. Journal / agency Twentyman OP, Disley A, Gribbin HR, Alberti KG, Tattersfield AE. Effect of beta-adrenergic blockade on respiratory and metabolic responses to exercise. Journal of Applied Physiology. October 1981. doi:10.1152/jappl.1981.51.4.788 · PMID 6795164
24. Journal / agency Richter EA, Galbo H, Christensen NJ. Control of exercise-induced muscular glycogenolysis by adrenal medullary hormones in rats. Journal of Applied Physiology. January 1981. doi:10.1152/jappl.1981.50.1.21 · PMID 7009527
25. Journal / agency Cannon WB. Studies on the conditions of activity in endocrine organs xxvii. Evidence that medulliadrenal secretion is not continuous. The American Journal of Physiology. 1931. doi:10.1152/ajplegacy.1931.98.3.447
26. Journal / agency Cryer PE, Tse TF, Clutter WE, Shah SD. Roles of glucagon and epinephrine in hypoglycemic and nonhypoglycemic glucose counterregulation in humans. The American Journal of Physiology. August 1984. doi:10.1152/ajpendo.1984.247.2.E198 · PMID 6147094
27. Journal / agency Hartman FA, Waite RH, McCordock HA. The liberation of epinephrine during muscular exercise. The American Journal of Physiology. 1922. doi:10.1152/ajplegacy.1922.62.2.225
28. Journal / agency Von Euler US, Hellner S. Excretion of noradrenaline and adrenaline in muscular work. Acta Physiologica Scandinavica. September 1952. doi:10.1111/j.1748-1716.1952.tb00900.x · PMID 12985406
29. Journal / agency Lund A. Simultaneous fluorimetric determinations of adrenaline and noradrenaline in blood. Acta Pharmacologica et Toxicologica. 1950. doi:10.1111/j.1600-0773.1950.tb03460.x · PMID 24537959
30. Journal / agency Johnson GA, Kupiecki RM, Baker CA. Single isotope derivative (radioenzymatic) methods in the measurement of catecholamines. Metabolism. November 1980. doi:10.1016/0026-0495(80)90018-9 · PMID 7001177
31. Journal / agency Galbo H, Holst JJ, Christensen NJ. Glucagon and plasma catecholamine responses to graded and prolonged exercise in man. Journal of Applied Physiology. January 1975. doi:10.1152/jappl.1975.38.1.70 · PMID 1110246
32. Journal / agency Winder WW, Hagberg JM, Hickson RC, Ehsani AA, McLane JA. Time course of sympathoadrenal adaptation to endurance exercise training in man. Journal of Applied Physiology. September 1978. doi:10.1152/jappl.1978.45.3.370 · PMID 701121
33. Journal / agency Kindermann W, Schnabel A, Schmitt WM, Biro G, Hippchen M. Catecholamines, GH, cortisol, glucagon, insulin, and sex hormones in exercise and beta 1-blockade (author's transl). Klinische Wochenschrift. May 1982. doi:10.1007/bf01756096 · PMID 6124653
34. Journal / agency Warren JB, Dalton N, Turner C, Clark TJ, Toseland PA. Adrenaline secretion during exercise. Clinical Science. January 1984. doi:10.1042/cs0660087 · PMID 6690194
35. Journal / agency Fitzgerald GA, Barnes P, Hamilton CA, Dollery CT. Circulating adrenaline and blood pressure: the metabolic effects and kinetics of infused adrenaline in man. European Journal of Clinical Investigation. October 1980. doi:10.1111/j.1365-2362.1980.tb00052.x · PMID 6777175
36. Journal / agency Warren JB, Dalton N. A comparison of the bronchodilator and vasopressor effects of exercise levels of adrenaline in man. Clinical Science. May 1983. doi:10.1042/cs0640475 · PMID 6831836
37. Journal / agency Warren JB, Dalton N, Turner C, Clark TJ. Protective effect of circulating epinephrine within the physiologic range on the airway response to inhaled histamine in nonasthmatic subjects. The Journal of Allergy and Clinical Immunology. November 1984. doi:10.1016/0091-6749(84)90230-6 · PMID 6389647
38. Journal / agency Grossman M. Das muscarin-lungen-odem. Zeitschrift für klinische Medizin. 1887
39. Journal / agency Jackson DE. The pulmonary action of the adrenal glands. Journal of Pharmacology and Experimental Therapeutics. 1912. doi:10.1016/S0022-3565(25)03987-4
40. Journal / agency Kagawa J, Kerr HD. Effects of brief graded exercise on specific airway conductance in normal subjects. Journal of Applied Physiology. February 1970. doi:10.1152/jappl.1970.28.2.138 · PMID 5413299
41. Journal / agency Warren JB, Jennings SJ, Clark TJ. Effect of adrenergic and vagal blockade on the normal human airway response to exercise. Clinical Science. January 1984. doi:10.1042/cs0660079 · PMID 6228370
42. Journal / agency Jennings SJ, Warren JB, Pride NB. Airway caliber and the work of breathing in humans. Journal of Applied Physiology. July 1987. doi:10.1152/jappl.1987.63.1.20 · PMID 2957350
43. Journal / agency Mezzacappa ES, Katkin ES, Palmer SN. Epinephrine, arousal, and emotion: A new look at two-factor theory. Cognition and Emotion. 1999. doi:10.1080/026999399379320
44. Journal / agency Toth M, Ziegler M, Sun P, Gresack J, Risbrough V. Impaired conditioned fear response and startle reactivity in epinephrine-deficient mice. Behavioural Pharmacology. February 2013. doi:10.1097/FBP.0b013e32835cf408 · PMID 23268986 · PMC3558035
45. Journal / agency Cahill L, Alkire MT. Epinephrine enhancement of human memory consolidation: interaction with arousal at encoding. Neurobiology of Learning and Memory. March 2003. doi:10.1016/S1074-7427(02)00036-9 · PMID 12591227
46. Journal / agency Dornelles A, de Lima MN, Grazziotin M, Presti-Torres J, Garcia VA, Scalco FS, Roesler R, Schröder N. Adrenergic enhancement of consolidation of object recognition memory. Neurobiology of Learning and Memory. July 2007. doi:10.1016/j.nlm.2007.01.005 · PMID 17368053
47. Journal / agency Roozendaal B, McGaugh JL. Memory modulation. Behavioral Neuroscience. December 2011. doi:10.1037/a0026187 · PMID 22122145 · PMC3236701
48. Journal / agency Tully K, Bolshakov VY. Emotional enhancement of memory: how norepinephrine enables synaptic plasticity. Molecular Brain. May 2010. doi:10.1186/1756-6606-3-15 · PMID 20465834 · PMC2877027
49. Journal / agency Ferry B, Roozendaal B, McGaugh JL. Basolateral amygdala noradrenergic influences on memory storage are mediated by an interaction between beta- and alpha1-adrenoceptors. The Journal of Neuroscience. June 1999. doi:10.1523/JNEUROSCI.19-12-05119.1999 · PMID 10366644 · PMC6782651
50. Other Shen H. Illustrated Pharmacology Memory Cards: PharMnemonics. 2008
51. Journal / agency Arnall DA, Marker JC, Conlee RK, Winder WW. Effect of infusing epinephrine on liver and muscle glycogenolysis during exercise in rats. The American Journal of Physiology. June 1986. doi:10.1152/ajpendo.1986.250.6.E641 · PMID 3521311
52. Journal / agency Raz I, Katz A, Spencer MK. Epinephrine inhibits insulin-mediated glycogenesis but enhances glycolysis in human skeletal muscle. The American Journal of Physiology. March 1991. doi:10.1152/ajpendo.1991.260.3.E430 · PMID 1900669
53. Other Sircar S. Medical Physiology. 2007
54. Journal / agency Vasudevan NT, Mohan ML, Goswami SK, Naga Prasad SV. Regulation of β-adrenergic receptor function: an emphasis on receptor resensitization. Cell Cycle. November 2011. doi:10.4161/cc.10.21.18042 · PMID 22041711 · PMC3266006
55. Journal / agency Berg JM, Tymoczko JL, Stryer L. Biochemistry. 2002
56. Other Guideline 11.5: Medications in Adult Cardiac Arrest. December 2010
57. Journal / agency Chang YT, Huang WC, Cheng CC, Ke MW, Tsai JS, Hung YM, Huang NC, Huang MS, Wann SR. Effects of epinephrine on heart rate variability and cytokines in a rat sepsis model. Bosnian Journal of Basic Medical Sciences. February 2020. doi:10.17305/bjbms.2018.3565 · PMID 29984678 · PMC7029199
58. Journal / agency Burnett AM, Segal N, Salzman JG, McKnite MS, Frascone RJ. Potential negative effects of epinephrine on carotid blood flow and ETCO₂ during active compression-decompression CPR utilizing an impedance threshold device. Resuscitation. August 2012. doi:10.1016/j.resuscitation.2012.03.018 · PMID 22445865
59. Other Szablewski L. Glucose Homeostasis and Insulin Resistance. 2011
60. Journal / agency Skalski JH, Kuch J. Polish thread in the history of circulatory physiology. Journal of Physiology and Pharmacology. April 2006. PMID 16766800
61. Journal / agency Bates WH. The Use of Extract of Suprarenal Capsule in the Eye. New York Medical Journal. 16 May 1896
62. Journal / agency Takamine J. The isolation of the active principle of the suprarenal gland. The Journal of Physiology. 1901
63. Journal / agency Bennett MR. One hundred years of adrenaline: the discovery of autoreceptors. Clinical Autonomic Research. June 1999. doi:10.1007/BF02281628 · PMID 10454061
64. Journal / agency Rao Y. The First Hormone: Adrenaline. Trends in Endocrinology and Metabolism. June 2019. doi:10.1016/j.tem.2019.03.005 · PMID 31064696
65. Journal / agency Ball CM, Featherstone PJ. The early history of adrenaline. Anaesthesia and Intensive Care. May 2017. doi:10.1177/0310057X1704500301 · PMID 28486885
66. Journal / agency Arthur G. Epinephrine: A Short History. The Lancet. Respiratory Medicine. May 2015. doi:10.1016/S2213-2600(15)00087-9 · PMID 25969360
67. Other Nelson L, Cox M. Lehninger Principles of Biochemistry. 2004
68. Other SLC18 family of vesicular amine transporters
69. Journal / agency Oanca G, Stare J, Mavri J. How fast monoamine oxidases decompose adrenaline? Kinetics of isoenzymes A and B evaluated by empirical valence bond simulation. Proteins. December 2017. doi:10.1002/prot.25374 · PMID 28836294
70. Other Jänig W. The integrative action of the autonomic nervous system: neurobiology of homeostasis. 6 July 2006
71. Other Deane WH, Rubin BL. The Adrenocortical Hormones Their Origin – Chemistry Physiology and Pharmacology
72. Journal / agency Frankenhaeuser M, Jarpe G, Matell G. Effects of intravenous infusions of adrenaline and noradrenaline on certain psychological and physiological functions. Acta Physiologica Scandinavica. February 1961. doi:10.1111/j.1748-1716.1961.tb02126.x · PMID 13701421
73. Other Wise J. When Fear Makes Us Superhuman. 28 December 2009
74. Other Wise J. Extreme Fear: The Science of Your Mind in Danger. 8 December 2009

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.